UMC, TTUHSC announces groundbreaking findings to shrink tumors, prolong survival in Kidney Cancer patients
A groundbreaking study shows findings that show a treatment can shrink tumors and improve survival outcomes for patients with ...
Is Merck Stock a Buy?
It's been a rough start to 2025 for Merck (NYSE: MRK) shareholders following a less-than-stellar fourth-quarter earnings ...
Parade on MSN1d
'I Was Diagnosed With Uterine Cancer At 56—This Was the First Symptom I Noticed'
Uterine cancer (also known as endometrial cancer) is the fourth most common cancer women in the U.S. are diagnosed with. It ...
BioSpace2d
5 Pharma Powerhouses Facing Massive Patent Cliffs—And What They’re Doing About It
Merck’s Keytruda may be the most talked about drug facing loss of exclusivity but it’s far from the only one, as several of ...
C&EN2d
Long COVID studies stymied by pharma’s lack of cooperation
Pembrolizumab is a checkpoint inhibitor that binds to the protein PD-1 on T cells to help them recognize and attack invaders.
The Economist5d
It’s not just AI. China’s medicines are surprising the world, too
Its firms are at the forefront of cheaper, faster drug discovery ...
Better High-Yield Dividend Stock: Pfizer vs. Merck
Eliquis, a blood thinner marketed in partnership with Bristol Myers Squibb, is Pfizer's largest revenue stream at the moment.
Cure Today1d
Ficerafusp Alfa Trial Begins for Recurrent/Metastatic Head and Neck Cancer
Ficerafusp alfa enters phase 2/3 trial for recurrent/metastatic head and neck cancer, evaluating its combination with Keytruda for first-line treatment.
Want Decades of Passive Income? 2 Stocks to Buy Now and Hold Forever.
Most companies don't survive for decades, much less pay regular dividends for that long. Healthcare leaders Merck (NYSE: MRK) ...